UB Paderborn / Katalog / Suche / in CDI

26 – 50 von 134

Sortiert nach

Phase 1 Study of AMG 386, a Selective Angiopoietin 1/2-Neutralizing Peptibody, in Combination with Chemotherapy in Adults with Advanced Solid Tumors

Clinical cancer research, 2010-06, Vol.16 (11), p.3044-3056

2010

Volltextzugriff (PDF)

Pharmacokinetics and Safety of Bortezomib in Patients with Advanced Malignancies and Varying Degrees of Liver Dysfunction: Phase I NCI Organ Dysfunction Working Group Study NCI-6432

Clinical cancer research, 2012-05, Vol.18 (10), p.2954-2963

2012

Volltextzugriff (PDF)

Design, conduct, and interpretation of organ impairment studies in oncology patients

Journal of clinical oncology, 2006-07, Vol.24 (21), p.3509-3510

2006

Volltextzugriff (PDF)

Maximum tolerated dose: clinical endpoint for a bygone era?

Targeted oncology, 2009-04, Vol.4 (2), p.143-147

Takimoto, Chris H.

2009

Volltextzugriff (PDF)

Two Drug Interaction Studies Evaluating the Pharmacokinetics and Toxicity of Pemetrexed When Coadministered with Aspirin or Ibuprofen in Patients with Advanced Cancer

Clinical cancer research, 2006-01, Vol.12 (2), p.536-542

2006

Volltextzugriff (PDF)

Improving attribution of adverse events in oncology clinical trials

Cancer treatment reviews, 2019-06, Vol.76, p.33-40

2019

Volltextzugriff (PDF)

Pharmacokinetics and pharmacodynamic biomarkers in early oncology drug development

European journal of cancer (1990), 2009-09, Vol.45, p.436-438

Takimoto, Chris H

2009

Volltextzugriff (PDF)

A Phase I and Pharmacokinetic Study of Squalamine, an Aminosterol Angiogenesis Inhibitor

Clinical cancer research, 2003-07, Vol.9 (7), p.2465-2471

2003

Volltextzugriff (PDF)

Phase 0 clinical trials in oncology: a paradigm shift for early drug development?

Cancer chemotherapy and pharmacology, 2009-03, Vol.63 (4), p.703-709

Takimoto, Chris H

2009

Volltextzugriff (PDF)

Two phase I, pharmacokinetic, and pharmacodynamic studies of DFP-10917, a novel nucleoside analog with 14-day and 7-day continuous infusion schedules

Investigational new drugs, 2019-02, Vol.37 (1), p.76-86

2019

Volltextzugriff (PDF)

A Phase I, Pharmacokinetic, and Biological Study of the Farnesyltransferase Inhibitor Tipifarnib in Combination with Gemcitabine in Patients with Advanced Malignancies

Clinical cancer research, 2003-10, Vol.9 (13), p.4761-4771

2003

Volltextzugriff (PDF)

Commentary: Tumor Growth, Patient Survival, and the Search for the Optimal Phase II Efficacy Endpoint

The oncologist (Dayton, Ohio), 2008-10, Vol.13 (10), p.1043-1045

Takimoto, Chris H.

2008

Volltextzugriff (PDF)

Dose-escalating and pharmacological study of bortezomib in adult cancer patients with impaired renal function: a National Cancer Institute Organ Dysfunction Working Group Study

Cancer chemotherapy and pharmacology, 2011-12, Vol.68 (6), p.1439-1447

2011

Volltextzugriff (PDF)

Phase I and Pharmacokinetic Study of Sequences of the Rebeccamycin Analogue NSC 655649 and Cisplatin in Patients with Advanced Solid Tumors

Clinical cancer research, 2005-12, Vol.11 (24), p.8728-8736

2005

Volltextzugriff (PDF)

Using Pharmacokinetic and Pharmacodynamic Data in Early Decision Making Regarding Drug Development: A Phase I Clinical Trial Evaluating Tyrosine Kinase Inhibitor, AEE788

Clinical cancer research, 2012-11, Vol.18 (22), p.6364-6372

2012

Volltextzugriff (PDF)

Chronomodulated chemotherapy for colorectal cancer: Failing the test of time?

European journal of cancer (1990), 2006-03, Vol.42 (5), p.574-581

Takimoto, Chris H.

2006

Volltextzugriff (PDF)

A Phase I and Pharmacokinetic Study of ILX-295501, an Oral Diarylsulfonylurea, on a Weekly for 3 Weeks Every 4-Week Schedule in Patients with Advanced Solid Malignancies

Clinical cancer research, 2003-11, Vol.9 (15), p.5540-5549

2003

Volltextzugriff (PDF)

Specific binding of human dihydrofolate reductase protein to dihydrofolate reductase messenger RNA in vitro

Biochemistry (Easton), 1993-05, Vol.32 (18), p.4756-4760

1993

Volltextzugriff (PDF)

Anticancer drug development at the US National Cancer Institute

Cancer chemotherapy and pharmacology, 2003-07, Vol.52, p.S29-S33

TAKIMOTO, Chris H

2003

Volltextzugriff (PDF)

Phase I study of paclitaxel poliglumex administered weekly for patients with advanced solid malignancies

Cancer chemotherapy and pharmacology, 2009-07, Vol.64 (2), p.287-295

2009

Volltextzugriff (PDF)

A phase I pharmacokinetic study of bexarotene with paclitaxel and carboplatin in patients with advanced non-small cell lung cancer (NSCLC)

Cancer chemotherapy and pharmacology, 2012-03, Vol.69 (3), p.825-834

2012

Volltextzugriff (PDF)

Effects of patupilone on the pharmacokinetics and pharmacodynamics of warfarin in patients with advanced malignancies: a phase I clinical trial

Molecular cancer therapeutics, 2011-01, Vol.10 (1), p.209-217

2011

Volltextzugriff (PDF)

The effect of bexarotene on atorvastatin pharmacokinetics: results from a phase I trial of bexarotene plus chemotherapy in patients with advanced non-small cell lung cancer

Cancer chemotherapy and pharmacology, 2012-02, Vol.69 (2), p.563-571

2012

Volltextzugriff (PDF)

Phase I and Pharmacokinetic Trial of Weekly Oral Fluorouracil Given With Eniluracil and Low-Dose Leucovorin to Patients With Solid Tumors

Journal of clinical oncology, 2000-12, Vol.18 (23), p.3952-3963

2000

Volltextzugriff (PDF)

A Phase I Pharmacologic and Pharmacodynamic Study of Pyrazoloacridine Given as a Weekly 24-Hour Continuous Intravenous Infusion in Adult Cancer Patients

Clinical cancer research, 2002-07, Vol.8 (7), p.2149-2156

2002

Volltextzugriff (PDF)

26 – 50 von 134

Suche als RSS-Feed

Suchergebnisse filtern

Filter anzeigen

Nur zeigen

Geprüft (Peer-Review)
(117)
Mit Volltextzugriff
(117)

Publikationsform

Sprache

Englisch
(134)
Japanisch
(10)

Erscheinungsjahr

n.n

Thema

Humans
(87)
Science & Technology
(84)
Life Sciences & Biomedicine
(83)
Oncology
(71)
Biological And Medical Sciences
(62)
Medical Sciences
(59)
Male
(55)
Female
(54)
Middle Aged
(50)
Pharmacology. Drug Treatments
(50)
Adult
(49)
Neoplasms - Drug Therapy
(47)
Antineoplastic Agents
(46)
Aged
(44)
Chemotherapy
(26)
Pharmacology & Pharmacy
(23)
Aged, 80 And Over
(21)
Antineoplastic Agents - Pharmacokinetics
(20)
Dose-Response Relationship, Drug
(20)
Infusions, Intravenous
(18)

15 weitere anzeigen...

Weniger anzeigen...

Menü

Weitere Dienste

Einstellungen

Phase 1 Study of AMG 386, a Selective Angiopoietin 1/2-Neutralizing Peptibody, in Combination with Chemotherapy in Adults with Advanced Solid Tumors

Pharmacokinetics and Safety of Bortezomib in Patients with Advanced Malignancies and Varying Degrees of Liver Dysfunction: Phase I NCI Organ Dysfunction Working Group Study NCI-6432

Design, conduct, and interpretation of organ impairment studies in oncology patients

Maximum tolerated dose: clinical endpoint for a bygone era?

Two Drug Interaction Studies Evaluating the Pharmacokinetics and Toxicity of Pemetrexed When Coadministered with Aspirin or Ibuprofen in Patients with Advanced Cancer

Improving attribution of adverse events in oncology clinical trials

Pharmacokinetics and pharmacodynamic biomarkers in early oncology drug development

A Phase I and Pharmacokinetic Study of Squalamine, an Aminosterol Angiogenesis Inhibitor

Phase 0 clinical trials in oncology: a paradigm shift for early drug development?

Two phase I, pharmacokinetic, and pharmacodynamic studies of DFP-10917, a novel nucleoside analog with 14-day and 7-day continuous infusion schedules

A Phase I, Pharmacokinetic, and Biological Study of the Farnesyltransferase Inhibitor Tipifarnib in Combination with Gemcitabine in Patients with Advanced Malignancies

Commentary: Tumor Growth, Patient Survival, and the Search for the Optimal Phase II Efficacy Endpoint

Dose-escalating and pharmacological study of bortezomib in adult cancer patients with impaired renal function: a National Cancer Institute Organ Dysfunction Working Group Study

Phase I and Pharmacokinetic Study of Sequences of the Rebeccamycin Analogue NSC 655649 and Cisplatin in Patients with Advanced Solid Tumors

Using Pharmacokinetic and Pharmacodynamic Data in Early Decision Making Regarding Drug Development: A Phase I Clinical Trial Evaluating Tyrosine Kinase Inhibitor, AEE788

Chronomodulated chemotherapy for colorectal cancer: Failing the test of time?

A Phase I and Pharmacokinetic Study of ILX-295501, an Oral Diarylsulfonylurea, on a Weekly for 3 Weeks Every 4-Week Schedule in Patients with Advanced Solid Malignancies

Specific binding of human dihydrofolate reductase protein to dihydrofolate reductase messenger RNA in vitro

Anticancer drug development at the US National Cancer Institute

Phase I study of paclitaxel poliglumex administered weekly for patients with advanced solid malignancies

A phase I pharmacokinetic study of bexarotene with paclitaxel and carboplatin in patients with advanced non-small cell lung cancer (NSCLC)

Effects of patupilone on the pharmacokinetics and pharmacodynamics of warfarin in patients with advanced malignancies: a phase I clinical trial

The effect of bexarotene on atorvastatin pharmacokinetics: results from a phase I trial of bexarotene plus chemotherapy in patients with advanced non-small cell lung cancer

Phase I and Pharmacokinetic Trial of Weekly Oral Fluorouracil Given With Eniluracil and Low-Dose Leucovorin to Patients With Solid Tumors

A Phase I Pharmacologic and Pharmacodynamic Study of Pyrazoloacridine Given as a Weekly 24-Hour Continuous Intravenous Infusion in Adult Cancer Patients

Suchergebnisse filtern